[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alterity Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100649065","phase-2-open-label-access-to-ath434-for-patients-who-completed-study-ath434-201-in-france-100649065",false,"NCT07729852","Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France","Open-Label Extension Study to Provide Access to ATH434 in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Completed Alterity protocol ATH434-201.\n* Expected to benefit from treatment from treatment with ATH434, in the opinion of the Investigator.\n\nExclusion Criteria:\n\n* Discontinued prior ATH434 treatment (ATH434-201) for any reason.\n* Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the Investigator's opinion.","ALL",{"count":18,"type":19},5,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.",[25],"Multiple System Atrophy","NOT_YET_RECRUITING","2026-07-22",{"date":29,"type":30},"2026-07-28","ACTUAL",{"date":32,"type":19},"2026-07",{"date":34,"type":19},"2029-07",{"name":36,"class":37},"Alterity Therapeutics","INDUSTRY",4,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":45,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":52,"locationsCount":4},"100633803","post-trial-access-to-ath434-for-patients-with-multiple-system-atrophy-100633803","NCT07531433","Post-Trial Access to ATH434 for Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Completed Alterity protocol ATH434-201 or ATH434-202\n* Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician\n\nExclusion Criteria:\n\n* Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason\n* Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion","EXPANDED_ACCESS","This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.",[25],"AVAILABLE","2026-04-09",{"date":51,"type":30},"2026-04-15",{"name":36,"class":37},""]